TABLE 3.
UL40 sequence adaptionsa
| Patient ID | D/R serostatus | HLA-E genotype | UL40 V1 (SMM IC50 [nM]) | UL40 V2 (SMM IC50 [nM]) |
|---|---|---|---|---|
| 18 | D+/R+ | R: *0101/0101 D: *0101/0101 | VLAPRTLLL (0101: 111.5) | VMTPRTLIL (0101: 60.8) |
| 19 | D+/R+ | R: *0103/0103 D: *0103/0103 | VMTPRTLIL (0103: 8,674.4) | VMAPRTLIL (0103: 10,333.3) |
| 20 | D+/R+ | R: *0103/0103 D: *0101/0101 | VMAPRTLLL (0101: 45; 0103: 10,333.3) | VMAPRTLVL (0101: 45; 0103: 10,333.3) |
a
Abbreviations: D+, HCMV-seropositive donor; D−, HCMV-seronegative donor; R+, HCMV-seropositive recipient; R−, HCMV-seronegative recipient; V, viremic episode. IC50, 50% inhibitory concentration.